Why I’m Buying AstraZeneca plc At Current Prices

Here’s why I’m buying AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Throughout 2014, I wasn’t a fan of AstraZeneca (LSE: AZN). However, last week I started to build a position in the company.

You see, over the past few months my opinion of Astra has changed.

True, the company is still suffering from the loss of exclusive manufacturing rights on some its key treatments, but the group’s outlook is improving.

Falling sales

Falling sales of Astra’s blockbuster Crestor and Nexium drugs, which together accounted for a third of overall sales during 2014, are holding the company back. 

In March, management warned that due to falling sales of these key treatments, revenue for full-year 2015 is expected to decline by mid-single digit percentage. 

Still, Astra’s growth initiatives are coming on in leaps and bounds.

Specifically, during the first quarter of this year, Astra’s five growth platforms –Brilinta, Diabetes, Respiratory Emerging Markets and Japan — reported sales growth of 13%.

Further, the company’s productivity agenda has started to yield results. While sales are set to fall during 2015, due to cost savings, core earnings per share are expected to increase by low single-digit percentage. 

Bright outlook

It’s nice to see that Astra’s efforts to stem falling sales are taking hold, but that’s not why I’m interested in the company.

I’m really interested in Astra’s future growth potential. 

The company has 119 projects in its clinical development pipeline. During 2015-2016 alone, around a third of these will progress to the next stage of development. What’s more, Astra is currently conducting 72 trials for its oncology treatments under development. Some of these trails have already yielded substantial results. 

Unfortunately, if history is anything to go by, only a small number of the treatments Astra is currently developing will make it to market. Figures show that on average, less than 10% of drugs make it from inception to sale. 

Nevertheless, with 119 treatments under development, Astra stands to bring 12 new products to market over the next few years. 

Lofty targets

12 new products may not seem like much, but many of these drugs will be high-margin oncology treatments. 

And the key test will come over the next two years when Astra’s sales are set to being expanding again.

Astra’s long-term plan is to achieve sales of £45bn by 2023, which seems wishful thinking, although, with so many products under development, the company stands a good chance of hitting this target. 

Attractive valuation 

As I’ve mentioned before, if Astra manages to meet this lofty target, based on my figures and historic profit margins, the company could report a net profit around £5.6bn or 443p per share by 2023.

At present, Astra currently trades at a forward P/E of 15.6. 

15.6 times 2023’s projected earnings per share of 443p gives a target price of £69.11 by 2023. That’s an annual return of around 6.9%. Assuming Astra’s dividend yield remains at 4.2% and dividends are reinvested, in the best-case, investors could see a total return of 136% by 2023. 

Now, clearly this is an optimistic forecast but it really shows the growth potential Astra has ahead of it.

That’s why I’m a buyer.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »